Cassileth Bio

Article

Dr. Cassileth is chief of MSKCC’s Integrative Medicine Service and the Laurance S. Rockefeller Chair in Integrative Medicine.The program Dr. Cassileth built at MSKCC offers individual therapies in many areas, including various types of massage; mind-body therapies such as meditation, guided imagery, and self-hypnosis; creative therapies involving music and sound; acupuncture; nutrition counseling; fitness classes; education programs for patients, caregivers, and healthcare professionals; and evidence-based information on herbs, botanicals, and other products.Dr. Cassileth has continued to emphasize research, and she and her colleagues in the Integrative Medicine department serve as principal investigators for a number of ongoing trials at MSKCC, including studies of acupuncture and massage therapy.She has further promoted research of complementary therapies as founding president of the International Society for Integrative Oncology (SIO) and as a founding member of the advisory council to the National Institutes of Health Office of Alternative Medicine, now the National Center for Complementary and Alternative Medicine (NCCAM).For Dr. Cassileth, integrative medicine reflects the new era of oncology, one in which our excellent and growing survival rates permit attention to survivor needs. Physical and emotional sequelae of treatment now are important emphases.Complementary modalities can control many symptoms and enhance quality of life with safe, non-invasive, non-toxic interventions in which patients themselves can play an active role.

Dr. Cassileth is chief of MSKCC’s Integrative Medicine Service and the Laurance S. Rockefeller Chair in Integrative Medicine.

The program Dr. Cassileth built at MSKCC offers individual therapies in many areas, including various types of massage; mind-body therapies such as meditation, guided imagery, and self-hypnosis; creative therapies involving music and sound; acupuncture; nutrition counseling; fitness classes; education programs for patients, caregivers, and healthcare professionals; and evidence-based information on herbs, botanicals, and other products.

Dr. Cassileth has continued to emphasize research, and she and her colleagues in the Integrative Medicine department serve as principal investigators for a number of ongoing trials at MSKCC, including studies of acupuncture and massage therapy.

She has further promoted research of complementary therapies as founding president of the International Society for Integrative Oncology (SIO) and as a founding member of the advisory council to the National Institutes of Health Office of Alternative Medicine, now the National Center for Complementary and Alternative Medicine (NCCAM).

For Dr. Cassileth, integrative medicine reflects the new era of oncology, one in which our excellent and growing survival rates permit attention to survivor needs. Physical and emotional sequelae of treatment now are important emphases.

Complementary modalities can control many symptoms and enhance quality of life with safe, non-invasive, non-toxic interventions in which patients themselves can play an active role.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content